Trotabresib

CAS No. 1706738-98-8

Trotabresib( —— )

Catalog No. M34836 CAS No. 1706738-98-8

Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 215 In Stock
5MG 188 In Stock
10MG 312 In Stock
25MG 528 In Stock
50MG 739 In Stock
100MG 995 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Trotabresib
  • Note
    Research use only, not for human use.
  • Brief Description
    Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.
  • Description
    CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1706738-98-8
  • Formula Weight
    383.46
  • Molecular Formula
    C21H21NO4S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (130.39 mM; Ultrasonic )
  • SMILES
    Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.
molnova catalog
related products
  • C646

    C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM in a cell-free assay.

  • UNC?1021

    UNC 1021 is a selective L3MBTL3 inhibitor (IC50 = 0.048 μM).

  • PBRM1-BD2-IN-2

    PBRM1-BD2-IN-2, a selective and cell-active inhibitor of the polybromo-1 (PBRM1) bromodomain, exhibits binding affinity and inhibitory activity specifically targeting the PBRM1-BD2 domain, with Kd and IC50 values of 9.3 μM and 1.0 μM, respectively.